CD177, a specific marker of neutrophil activation, is a hallmark of COVID-19 severity and death

Levy, Y.; Wiedemann, A.; Hejblum, B. P.; Durand, M.; Lefebvre, C.; Surenaud, M.; Lacabaratz, C.; Perreau, M.; Foucat, E.; Dechenaud, M.; Tisserand, P.; Blengio, F.; Hivert, B.; Gautier, M.; Cervantes, M.; Bachelet, D.; Laouenan, C.; Bouadma, l.; Timsit, J.-F.; Yazdanpanah, Y.; Pantaleo, G.; Hocini, H.; Thiebaut, R.; Study Group, F. C.

COVID-19 SARS-CoV-2 infection exhibits wide inter-individual clinical variability, from silent infection to severe disease and death. The identification of high-risk patients is a continuing challenge in routine care. We aimed to identify factors that influence clinical worsening. We analyzed 52 cell populations, 71 analytes, and RNA-seq gene expression in the blood of severe patients from the French COVID-19 study upon hospitalization (n = 61). COVID-19 patients showed severe abnormalities of 27 cell populations relative to healthy donors (HDs). Forty-two cytokines, neutrophil chemo-attractants, and inflammatory components were elevated in COVID-19 patients. Supervised gene expression analyses showed differential expression of genes for neutrophil activation, interferon signaling, T- and B-cell receptors, EIF2 signaling, and ICOS-ICOSL pathways in COVID-19 patients. Unsupervised analysis confirmed the prominent role of neutrophil activation, with a high abundance of CD177, a specific neutrophil activation marker. CD177 was the most highly differentially-expressed gene contributing to the clustering of severe patients and its abundance correlated with CD177 protein serum levels. CD177 levels were higher in COVID-19 patients from both the French and confirmatory Swiss cohort (n = 203) than in HDs (P< 0.01) and in ICU than non-ICU patients (P< 0.001), correlating with the time to symptoms onset (P = 0.002). Longitudinal measurements showed sustained levels of serum CD177 to discriminate between patients with the worst prognosis, leading to death, and those who recovered (P = 0.01). These results highlight neutrophil activation as a hallmark of severe disease and CD177 assessment as a reliable prognostic marker for routine care.